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Abstract
Aims: Third-wave psychological interventions have gained relevance in mental health
service provision but their application to people with psychosis is in its infancy and
interventions targeting wellbeing in psychosis are scarce. This study tested the feasibility and
preliminary effectiveness of positive psychotherapy adapted for people with psychosis
(WELLFOCUS PPT) to improve wellbeing.
Methods: WELLFOCUS PPT was tested as an 11-week group intervention in a convenience
sample of people with psychosis in a single centre randomized controlled trial
(ISRCTN04199273) involving 94 people with psychosis. Patients were individually
randomized in blocks to receive either WELLFOCUS PPT in addition to treatment as usual
(TAU), or TAU only. Assessments took place before randomisation and after the therapy.
The primary outcome was wellbeing (Warwick-Edinburgh Mental Well-Being Scale).
Secondary outcomes included symptoms (Brief Psychiatric Rating Scale), depression (Short
Depression-Happiness Scale), self-esteem, empowerment, hope, sense of coherence,
savoring beliefs, and functioning, as well as two alternative measures of wellbeing (the
Positive Psychotherapy Inventory and Quality of Life). Intention-to-treat analysis was
performed. This involved calculating crude changes and paired-sample t-tests for all
variables, as well as ANCOVA and Complier Average Causal Effect Analysis to estimate the
main effect of group on all outcomes.
Results: The intervention and trial procedures proved feasible and well accepted. Crude
changes between baseline and follow-up showed a significant improvement in the
intervention group for wellbeing according to all three concepts assessed (i.e. Warwick-
Edinburgh Mental Well-Being Scale, Positive Psychotherapy Inventory, and Quality of Life),
as well as for symptoms, depression, hope, self-esteem, and sense of coherence. No
significant changes were observed in the control group. ANCOVA showed no main effect on
wellbeing according to the primary outcome scale (Warwick-Edinburgh Mental Well-Being
Scale) but significant effects on symptoms (p=.006, ES=.42), depression (p=.03, ES=.38)
and wellbeing according to the Positive Psychotherapy Inventory (p=.02, ES=.30).
Secondary analysis adapting for therapy group further improved the results for symptom
reduction (p=0.004, ES=0.43) and depression (p=.03, ES=0.41) but did not lead to any more
outcomes falling below the p=0.05 significance level. CACE analysis showed a non-
2significant positive association between the intervention and WEMWBS scores at follow-up
(b=.21, z=0.9, p=.4).
Conclusions: This study provides initial evidence on the feasibility of WELLFOCUS PPT in
people with psychosis, positively affecting symptoms and depression. However, more work is
needed to optimize its effectiveness. Future research might evaluate positive psychotherapy
as a treatment for comorbid depression in psychosis, and consider alternative measurements
of wellbeing.
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3Background
Whilst there is evidence that people who suffer from psychosis can have a favorable
prognosis (Zipursky et al. 2013), up to one third of patients with schizophrenia suffer
persistent psychotic symptoms despite adequate treatment (Miyamoto et al. 2014).
Consequently, new therapeutic approaches are being developed and tested, both biological
and psychological. In terms of psychological treatment strategies, cognitive behavioral
therapy (CBT) has the most advanced evidence base and is recommended for people at all
stages of a psychotic illness (NICE 2009). Recent meta-analytic evidence suggests a
beneficial effect of CBT for a range of subgroups of people with schizophrenia (Burns et al.,
2014) partly depending on the methods used in the respective trials (Jauhar et al. 2014).
Other new psychological interventions that have received increasing attention in recent years
include so called “third wave” cognitive behavioral therapies (Kahl et al. 2012) or more
humanistic and psychodynamically oriented approaches which gained additional prominence
with the establishment of Positive Psychology in the late 1990s (Sin & Lyubomirsky, 2009).
These therapeutic approaches often do not directly target symptom reduction or functioning,
but instead focus on subjective psychological variables such as wellbeing, life satisfaction or
meaning. Meta-analytic evidence supports the effectiveness of positively oriented
approaches for these variables, but also for the secondary improvement of symptoms (Bolier
et al. 2013, Sin & Lyubomirsky, 2009). While some positive interventions, e.g. mindfulness
therapy (Chadwick, 2014), have already been tested with people with psychosis, overall,
research on the application of positive interventions in this client group is still in its infancy.
The academic discipline of Positive Psychology focusses on improving wellbeing by
addressing positive aspects of human experience, strengths and positive resources
(Seligman et al. 2005). Positive Psychotherapy (PPT) constitutes the most comprehensive
therapeutic application of positive psychology principles (Rashid & Seligman, 2013). It was
developed for people with depressive symptoms and initial evaluation showed promising
results for improving wellbeing and ameliorating depression (Bolier et al. 2013, Sin &
Lyubomirsky, 2009). So far, PPT has been mainly applied to healthy people and those with
depression, but research in mental health settings is increasing and can overall be regarded
as preliminary but promising (Schrank et al, 2014). PPT principles appear to be applicable to
people with psychosis (Meyer et al. 2012), but it has not been systematically adapted for this
client group or tested using a randomized controlled design (Schrank et al, 2014).
We adapted PPT following the Medical Research Council (MRC) Guidelines for the
development and evaluation of complex interventions (Craig et al. 2008). This involved a
systematic literature review (Schrank et al. 2013a), qualitative study (Schrank et al. 2013b),
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intended to augment existing mental health practice to increase wellbeing. It is hypothesized
to also positively affect other indicators of improved wellbeing, i.e. positive emotions,
symptom relief, connectedness, hope, self-worth, empowerment, and meaning in life. These
variables were identified in preceding qualitative work with the client group with the specific
aim to understand the concept of wellbeing and the processes involved in improving it
(Schrank et al. 2013b) The aim of this pilot randomized controlled trial was to inform the
design of a future definitive RCT. The objectives were (1) to test relevant trial procedures,
especially in relation to (i) referral and consent rates, (ii) allocation procedures, (iii)
attendance and loss to follow-up, (iv) fidelity approaches, and (v) outcome assessment; and
(2) to establish preliminary evidence about the effectiveness of the intervention for improving
wellbeing, to inform a future sample size calculation.
Methods
Design
This study was a pilot RCT according to MRC guidelines for the development and evaluation
of complex interventions (Craig et al. 2008). Recommendations for pilot trials (Lancaster et
al. 2004, Thabane et al. 2010), were followed, and a trial protocol was published (Schrank et
al. 2013c). The study received ethical approval (12/LO/1960).
A target sample size of 30 complete data sets in each trial arm was chosen according to
recommendations for pilot trials (Lancaster et al. 2004). Recruitment took an expected 25%
drop-out into account. The obtained sample size allowed effectiveness at a medium effect
size (Cohen’s d = 0.5) to be detected with 90% power at a 5% significant level, taking into
account 20% attrition.
Participants
Inclusion criteria were: aged 18-65 years; primary clinical diagnosis of psychosis defined as
schizophrenia and other psychoses including schizoaffective and delusional disorder but not
depressive psychosis or psychosis due to substance misuse; current use of adult mental
health services; fluency in English; and ability to give informed consent and participate in
group therapy in the opinion of the key clinician.
Intervention and control condition
Control group participants received treatment as usual (TAU), consistent with the Care
Programme Approach (Department of Health, 1999), comprising systematic assessments of
health and social needs, formation of a care plan, appointment of a key worker to monitor
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multidisciplinary mental health teams, and treatments may include medication, social or
psychological interventions. There was no restriction on changes to concurrent routine drug,
psychological or social therapies. No psychological intervention based on positive
psychology principles was routinely provided in the NHS services from which participants
were recruited.
Intervention group participants received TAU and 11 weekly 90-minute sessions of
WELLFOCUS PPT in a closed group format, delivered by a therapist and co-therapist. Six
therapy groups ran between May and October 2013. The five involved therapists were
routine NHS staff. Four of them were clinical psychologists with standard psychotherapy
training, mainly cognitive behavioral therapy (CBT)-focused, who were experienced in
delivering both individual and group therapeutic interventions to people with psychosis. One
was a trainee clinical psychologist under supervision. The three co-therapists were members
of the research team, one psychiatrist with a clinical education in CBT and two post-graduate
psychologists. All therapists and co-therapists were offered a 1.5 day intensive training
course and monthly peer supervision which included the developers of the intervention and
project staff who repeatedly provided the intervention as co-therapists. Training covered the
differences between WELLFOCUS PPT and CBT.
WELLFOCUS PPT is described in detail elsewhere (Riches et al. 2014). In brief, it targets
four areas of development: increasing positive experiences; amplifying strengths; fostering
positive relationships; and creating a more meaningful self-narrative. These areas are
addressed using ten exercises adapted from standard PPT: positive introductions, savoring,
good things, identifying personal strengths, personal strength activity, strength activity with
significant other, forgiveness, one door closes another door opens, gratitude, and positive
responding. Sessions begin and close with a music savoring exercise. In contrast to standard
PPT, WELLFOCUS PPT has a reduced focus on literacy and didactics but instead includes
more experiential and interactive components. All exercises and homework tasks are tailored
to the individual to be specific, attainable, and personally meaningful. Distinctive features are
the importance of valuing small things and the participation of therapists in all exercises.
Negative issues and experiences are dealt with by identifying and using positives, e.g.
personal strengths, to develop coping strategies. Participants receive a phone call between
sessions to support them with homework and reflect on what they have learnt.
Measures
The choice of outcome measures was informed by preceding conceptual research (Schrank
et al. 2013b). The primary outcome measure was the 14-item Warwick-Edinburgh Mental
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multi-dimensional construct with mean scores between 1 and 5 (Tennant et al. 2007). The
scale integrates several of the pre-existing concepts and measurement tools for wellbeing
and has proven feasible, reliable and sensitive to change in people with various mental
health problems, including some participants with psychosis (Margrove et al. 2012).
Cronbach’s α for the scale lies between 0.87 and 0.91 and the one-week test-retest reliability 
at r=0.83 (Clarke et al. 2011, Tennant et al. 2007).
Two alternative wellbeing measures were used: (i) the 25-item Positive Psychotherapy
Inventory (PPI) measures a PPT-specific concept of wellbeing with mean scores between 1
and 5 (Guney, 2011), and (ii) the 12-item Manchester Short Assessment (MANSA) measures
quality of life framed as satisfaction with life as a whole and with specific life domains (Priebe
et al. 1999), with mean scores between 1 and 7.
Six indicators of wellbeing, as identified in qualitative research with the client group (Schrank
et al. 2013b), were measured. The Savoring Beliefs Inventory (SBI) is a 24-item scale
assessing the ability to derive pleasure through anticipating upcoming positive events,
savoring positive moments in the present, and reminiscing about past positive experiences,
with scores ranging between 1 and 7 (Bryant, 2003). The Integrative Hope Scale (IHS) is a
23-item scale that captures a comprehensive concept of hope and produces mean scores
ranging between 1 and 6 (Schrank et al. 2012). The Rogers Empowerment Scale (RES) is a
28-item instrument measuring subjective feelings of empowerment resulting in mean scores
between 1 and 4 (Rogers et al. 2010). The Rosenberg Self-Esteem Scale (RSE-S) contains
10 items measuring self-esteem with mean scores ranging between 0 and 3 (Blaskovich &
Tomaka, 1991). The Sense of Coherence Scale (SCS) contains 29 questions to measure a
person’s global orientation to view their environment as comprehensible, manageable, and
meaningful. Mean scores range between 1 and 7 (Eriksson & Lindstrom, 2006). The Short
Depression-Happiness Scale (SDHS) measures affect on a bipolar continuum between
depression and happiness (Joseph & McCollam, 1993). It yields one overall score and two
sub-scores which separately show depression and happiness. Mean scores range between 1
and 4 (Joseph et al. 2004).
In addition we used the Health of the Nation Outcome Scale (HoNOS), a 12-item measure of
social disability covering a range of problem areas and sum scores ranging between 0 and
48 (Pirkis et al. 2005); the Brief Psychiatric Rating Scale (BPRS), an 18-item measure of
psychiatric symptom severity with sum scores ranging between 18 and 126 (Overall &
Gorham, 1988); and the Sociodemographics Form - Service User (SF-SU), a non-
standardized measure modified from another RCT (Slade et al. 2011) recording
sociodemographics, diagnosis and years using mental health services.
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with mental health problems, including psychosis. All measures, except for the BPRS and
HoNOS, were participant-rated. Assessments lasted between 45 and 120 minutes.
Procedures
Participants were recruited between April and August 2013 from eight teams in one mental
health service in South London, UK: two specialist psychosis community services holding
registers of service-users interested in participating in research, five community mental
health teams and one inpatient rehabilitation service. Letters about the WELLFOCUS Trial
were sent to members of the research registers. Care-coordinators from the other teams
were asked to refer potential participants to the research team. All participants were
contacted via telephone, received information about the study and, having given assent,
booked an interview for informed consent procedures and baseline measures.
Randomization was independently conducted after baseline, by the King’s Clinical Trials Unit
(registration number 053), in groups of 8 to 20 participants (as block randomization
representing multiples of 2 and 4 people). Follow-up interviews took place within two weeks
of the intervention finishing. Assessors were not involved in therapy provision, but were not
blinded to intervention status. Raters were changed between baseline and follow-up, but as
all worked in the same research team, the resources required for adequate allocation
concealment would have been disproportionate for a pilot study (Craig et al. 2008). Fidelity
evaluation followed the framework of the NIHBCC Treatment Fidelity Workgroup, including
the levels of provider training, treatment delivery and treatment receipt (Bellg et al. 2004).
Detailed notes were taken at each session by the co-therapist and then independently rated
by the research team using a fidelity scale specifically developed to assess the specific
content of WELLFOCUS PPT. Qualitative process evaluation employing individual interviews
and focus groups was undertaken with intervention group participants and therapists after
the follow-up assessments.
Analysis
A proportion (21%) of the data was double-entered, with a concordance rate of 99.96%. Up
to two missing items per questionnaire were pro-rated, and only one questionnaire (IHS) was
excluded for one person due to more than two missing items. Normality of the data
distribution was confirmed using the Shapiro-Wilks test, box-plots, and Q-Q plots. Therefore
parametric statistical methods were applied. Mean differences between baseline and follow-
up and paired sample t-tests were calculated for all assessed variables. ANCOVA was used
for intention-to-treat (ITT) analysis controlling for baseline score for all participants with
complete data. Secondary analysis adjusted for therapy group to control for effect
modification. Standardized effect size (Cohen’s d) was calculated. Complier Average Causal
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compliers on the primary outcome. The CACE model including baseline scores was fitted
using the two-stage least squares estimation method. Compliance was defined as attending
more than 50% of the sessions (i.e. 6 or more). To estimate feasibility and trial parameters
for a definitive RCT, referral and consent rates, rates of intervention receipt, attendance and
loss to follow-up were calculated. Logistic regression was used to explore the influence of
process times on attendance. Samples sizes needed for a definitive trial (ANCOVA) were
calculated using the means in the intervention group, pooled standard deviations, and
correlations between baseline and follow-up.
Qualitative process evaluation data from participants and facilitators were audio-recorded
and transcribed verbatim and supplemented with researcher notes and feedback. Content
analysis was applied, which identifies predefined entities of meaning from the data, i.e.
specific categories designed to be mutually exclusive (Neuendorf, 2002). Qualitative analysis
was conducted independently by two researchers to enhance reliability, with results
compared and discrepancies resolved through discussion.
Results
Participants
The flow diagram for the 94 study participants is shown in Figure 1.
Insert Figure 1 here
Baseline participant characteristics are shown in Table 1. As expected, participant
characteristics were balanced in the two arms after randomization.
Insert Table 1 here
WELLFOCUS PPT was provided to six groups, and each group had an average of 8 (range
4 to 10) participants. The median number of sessions attended was 7.
Objective 1: Testing trial procedures
Referral and consent rates
Forty-seven care-coordinators referred potential participants to the research. The mean
overall consent rate was 40.2% (35.9% for those referred by care coordinators, and 81.8%
for those contacted via research registers). For the 124 people who declined to take part in
the study at initial contact, the most frequently given reason was dislike of group therapy
(N=26). Other reasons included: timing of the therapy (N=19); location (N=12); dislike of
questionnaires (N=16); no interest in PPT (N=13); no need for therapy (N=5); no experience
9of psychosis (N=1); already doing another therapy (N=1), and no reason provided (N=26).
Six participants who originally expressed interest could not be contacted again.
Allocation procedures
Feedback from participants on the process of randomization was generally positive, with only
two suggesting that randomization was not fair and ways of dealing with unpreferred
allocation should be discussed before randomization. Mean time from referral to baseline
assessment was 18.6 (s.d. 12.9) days and from baseline assessment to first group 11.7 (s.d.
4.2) days. Completer status was not predicted by waiting time (referral to assessment
OR=0.99, z=-0.4, p=0.69, assessment to first group OR=1.01, z=0.2, p=0.87). Four
intervention group participants attended no sessions.
Attendance and loss to follow-up
Mean attendance rate was 54.2% (range 38% to 80%) sessions, and 26 (55%) of the 47
intervention group participants were completers. A total of 84 (89.4%) participants had
baseline and follow-up data. The difference in the proportion of drop-outs between the two
groups was not significant (z= 0.669, p=0.503). Drop-outs did not differ significantly from non
drop-outs in gender (chi2), age, wellbeing or symptoms (t-tests) at baseline.
Reported reasons for non-attendance were mental or physical illness (N=5),
hospital/physician appointments (N=5), being otherwise occupied (N=5), location (N=3),
transport costs (N=2), family needs (N=2), anxiety of attending group sessions (N=1),
delusions/voices preventing attendance (N=1); disorganization (N=2), low mood and lack of
motivation (N=2), not getting on with other people and lack of enjoyment of the first session
(N=1), misunderstanding the nature of the study (N=1), and not being reminded by hostel
staff to attend (N=1).
Fidelity assessment
Fidelity evaluation at the level of provider training revealed 100% attendance at therapist
PPT training and 60.7% attendance at the monthly peer supervision. Qualitative analysis of
therapist interviews suggested time constraints and location as the main reasons for non-
attendance. Corresponding suggestions to improve attendance were choosing a convenient
location and paying therapists. To ensure fidelity at the level of treatment delivery, therapists
were requested to meet before each session with co-therapists to discuss the session
content. Compliance with these pre-session meetings was 100%. Fidelity assessment at the
level of treatment receipt revealed a 97% content coverage across all therapy groups.
Objective 2: Estimating effectiveness and informing sample size
Treatment effect
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No adverse events were reported. Given the low rate of missing items in questionnaires with
only one necessary exclusion of the IHS, reporting of all 84 participants with follow-up
assessments is possible for all other scales. Raw data on change for all assessed variables
are presented in Table 2.
Insert Table 2 here
ITT analysis found no significant effect of intervention group on the primary outcome of
wellbeing (WEMWBS) at follow-up after adjusting for baseline scores (p=.37), and the effect
size was small (Cohen’s d=.15). Table 3 summarizes ITT analyses for all measures.
Insert Table 3 here
Adjusting the model for therapy group minimally increased effect sizes for the BPRS
(F(1,76)=8.7, p=0.004, ES=0.43), and SDHS depression (F(1,76)=4.9, p=-.03, ES=0.41) but
did not lead to any more outcomes falling below the p=0.05 significance level. In both
models, the highest effect sizes were found for symptom severity (BPRS) and depression
(SDHS depression), followed by wellbeing as measured by the PPI.
CACE analysis showed a non-significant positive association between the intervention and
WEMWBS scores at follow-up (b=.21, z=0.9, p=.4).
Outcome assessment and definitive sample size calculation
The exclusion due to missing data of only one of the 11 standardized outcome measures
from only one participant indicates the measures are acceptable and understandable to the
client group. Outliers were very rare, with most scales showing none, and MANSA, RES and
PPI between one and four. All scales showed highly significant correlations between baseline
and follow-up, with the strength of the correlation ranging from .58 (WEMWBS) to .83 (PPI).
Other scales which showed significant change due to the intervention in any of the analyses
had correlations of .83 (PPI), .71 (BPRS), and .65 (SDHS).
Based on the results of this study, the sample size for a definitive trial using the WEMWBS
as the main outcome measure (at a power of 0.9 and allowing for 20% drop-out) would have
to be 1,462 in order to obtain a statistically significant result. Necessary sample sizes for
those measures showing a significant result in the present study would have to be 125 for
the BPRS, 161 for the PPI, and 206 for SDHS depression.
Discussion
This is the first study to report a randomized controlled trial of positive psychotherapy
specifically adapted for people with psychosis. Results of the ITT analysis show a non-
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significant result for the primary and most secondary outcome measures, except for the
BPRS, SDHS depression and PPI which showed significant improvements in the intervention
as compared to the control group at moderate effect sizes.
Objective 1: Testing trial procedures
Recruitment of 94 participants in a short timescale suggests that the intervention had face
validity to the teams and individuals recruited. However, an overall consent rate of 40.0%
may not be achievable in a definitive trial with representative random sampling. The
randomization process was well accepted and successful overall. Waiting times between
referral and the start of therapy varied widely between individuals. However, this appeared
not to affect acceptability as waiting times were unrelated to completer status.
The attendance rate of 54.2% might be regarded as rather low. However, poor attendance
and completion rates are a known problem in intervention studies with people with severe
mental illness. This is especially true for exploratory trials with less enforcement and
monitoring of the intervention than in explanatory trials (Dunn, 2013, Ruggeri et al. 2013).
WELLFOCUS PPT was specifically designed as a service-user friendly and non-mandatory
offer to help increase wellbeing. Together with the 11-week duration of the group therapy and
the moderately symptomatic and long-term service use characteristics of participants this
may account for the attendance rate. Identified reasons for non-attendance suggest that
attendance in a definitive RCT could be increased through specific support, including regular
reminders, reassurance and discussing reasons for non-attendance.
The outcome evaluation strategy proved acceptable and feasible, and correlations between
baseline and follow-up results can inform sample size calculations for studies with similar
client groups. Fidelity assessment proved feasible and sensitive to deviations from fidelity
parameters. Overall fidelity was high, indicating that provider training, treatment delivery and
treatment receipt were reliably deliverable.
Objective 2: Estimating effectiveness and informing sample size
No significant effect of group was found on wellbeing as the main outcome. However, we
detected a significant improvement on the BPRS, with a moderate effect size in the ITT
analysis comparable to effect sizes found for CBT in this client group (Jauhar et al. 2014).
The BPRS is a researcher-rated scale, which in this non-blinded study might be susceptible
to detection bias. However, the likelihood of bias is reduced by the fact that equally strong
effects were found on the patient-rated SDHS depression sub-scale. This may be interpreted
as a triangulation to support the positive impact of WELLFOCUS PPT on symptomatology,
particularly depression. Nevertheless, in a blinded definitive RCT sample sizes may need to
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be increased for observer rated measures to yield statistically significant results, as blinding
is known to reduce effect size (Juni et al. 2001).
At least seven explanations might account for the lack of impact on wellbeing. First,
WELLFOCUS PPT may be truly ineffective for increasing wellbeing. However, in this pilot
study the sample size was not chosen to establish effectiveness, but for the primary purpose
of testing trial procedures and reliably estimating the sample size for a definitive RCT
(Lancaster et al. 2004, Thabane et al. 2010). Second, it may not be suitable for increasing
wellbeing within a timeframe of 11 weeks in people with psychosis. This argument is
supported by meta-analysis evidence showing that positive psychology interventions in
general are more effective when administered over relatively longer periods of time (Sin &
Lyubomirsky, 2009). However, controlled studies also showed that delivering PPT for a
period as short as six (Parks-Sheiner, 2009) or eight weeks (Ouweneel et al. 2013) can be
sufficient to statistically significantly increase wellbeing in healthy people, and that six weeks
are sufficient to increase wellbeing in people with substance abuse disorder (Akhtar &
Boniwell, 2010). Third, are indications that standard PPT may be more successful when
applied as individual therapy (Bolier et al., 2013). Similarly, the CBT literature mainly refers to
individual rather than group work and where the latter has been used it has been less
successful. It is possible that the same is true for WELLFOCUS PPT. Fourth, the WEMWBS
may not be sufficiently sensitive to detect change in people with psychosis. Whilst one
controlled intervention study applying the WEMWBS found it to be sensitive to change, the
respective participants were taken from a waiting list. They can therefore be assumed to
have been highly motivated, and most did not suffer from psychosis (Margrove et al. 2012).
Fifth, like the concept of recovery (Slade et al. 2012), the concept of wellbeing is complex.
There is no agreement in the literature on what it actually consists of (Schrank et al. 2013a).
The particular changes in wellbeing potentially brought about by WELLFOCUS may not be
captured by either the WEMWBS or the SDHS happiness sub-scale. By contrast, the PPI is
also a measure of wellbeing and it showed borderline significant changes attributable to the
intervention. The PPI was specifically developed to measure change following PPT. While
this may make it more responsive to change due to a positive psychotherapy intervention, it
may conversely be a process, rather than an outcome, measure. Sixth, the study design
which allowed all participants in the control group to receive any psychotherapeutic
intervention may have diluted the trial’s effect size. However, this is unlikely given the change
detected on secondary outcome measures. Seventh, the diverse experience of trial
therapists, the rather small amount of training they received, and their partly low compliance
with supervision may have diminished the positive effect of the intervention. This argument is
supported by research showing that not only therapist competence (Ruggeri & Tansella,
2011), but also experience and the amount of training can significantly influence trial results
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(Steel et al. 2012). However, therapists were highly qualified on entry into the study and the
intervention itself relatively intensive. This pilot trial tested a novel intervention for which
training was not yet available. A future definitive RCT can build on the experience from this
trial to inform therapist training and enforce attendance of supervision.
Strengths and limitations
As this study is the first to evaluate a new intervention, it is positioned as a pilot trial
according to the MRC framework for the development and evaluation of complex
interventions (Craig et al. 2008). Limitations include the non-random sampling, the use of
clinical instead of research diagnoses, unblinded outcome evaluation, the use of TAU instead
of an active comparison group, and non-monitoring of other psychological interventions.
Given that this was a group based intervention, more exploration of group cohesion and
other group process measures is also warranted as a possible intervening variable and
should be a focus of future research. A significant proportion of participants were non-white.
While all components of WELLFOCUS PPT were developed in the same culturally diverse
population and are hence sufficiently culturally adaptable to serve such a diverse participant
group, further exploration of cultural or religious implications for specific components, such
as the understanding of forgiveness, are worth investigating in future research.
Conclusions
This study provides initial evidence on the likely feasibility and acceptability of WELLFOCUS
PPT in the client group of people with psychosis. However, more work is needed to optimize
its effectiveness before a definitive RCT can be recommended. Initial results from the
qualitative process evaluation of this pilot study suggest particularly useful components
(Brownell et al, 2014) and will allow further optimization of the intervention manual.
WELLFOCUS PPT may be viable for reducing overall symptom severity and specifically
depression. Comorbid depression is a known challenge in the treatment of people with
psychosis, affecting about 50% of people with schizophrenia (Buckley et al. 2009). The
favorable effect of WELLFOCUS PPT on depressive symptoms needs to be evaluated
further, with specific attention to including research diagnoses and establishing the causal
pathway of action. Ways of supplementing the effect on symptoms in general are worth
considering in future research, including for example, a choice or combination of individual
and group work, or supplementing classic individual CBT with group WELLFOCUS PPT.
How to select those participants who are most likely to respond also remains an important
question for future research. In addition, a specific measurement challenge remains: how
best to assess wellbeing. Our two wellbeing measures showed very different responsiveness
to the intervention: WEMWBS did not change while the PPI consistently showed
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improvement. While a wide range of instruments suggested to measure wellbeing exist, only
few have established sensitivity to change, let alone in samples of people with psychosis
(Schrank et al., 2013d). Further research is needed to establish whether measuring
wellbeing is a technical problem requiring the rigorous development and evaluation of new
measures, or a conceptual problem caused by low validity in the construct of wellbeing
(Shepherd, 2014). This may include the exploration of sensitivity to change in existing
measures of wellbeing or related concepts such as hope. In either case, the goal of
supporting individuals to live well with psychosis remains.
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Figure 1: Participant flow in the WELLFOCUS Trial
Screened for eligibility
N = 234
Baseline interview scheduled
N = 110
Excluded: N = 124
Ineligible N = 0
Declined to participate N = 124
Randomised
N = 94
Randomised to intervention
N = 47
Lost to follow-up: N = 4
Could not contact N = 2
Withdrew consent N = 2
Randomised to control
N = 47
Lost to follow-up: N = 6
Could not contact N = 2
Withdrew consent N = 2
lllness N = 2
Baseline not completed: N = 16
Did not attend N = 13
Did not consent N = 2
Insufficient language skills N = 1
Analysed
N = 43
Analysed
N = 41
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Table 1: Sociodemographic and baseline clinical characteristics (n=94)
Intervention Control
Mean (SD) Mean (SD)
Age 43 (11.0) 42 (11.5)
n (%) n (%)
Gender Male 26 (55.3) 30 (63.8)
Ethnicity White 21 (44.7) 23 (50)
Non-White 26 (55.3) 23 (50)
Birth Place UK-born 29 (61.7) 27 (57.4)
Accommodation Owned 8 (17.0) 4 (8.5)
Rented 27 (57.4) 34 (72.3)
Other 12 (25.5) 8 (17.0)
Relationship Status Single 39 (83.0) 42 (89.4)
in Partnership 8 (17.0) 5 (10.6)
Qualifications None 5 (10.9) 2 (4.3)
Secondary education (11-16 years) 11 (25.6) 16 (34.8)
Further education (16-18 years) 11 (25.6) 12 (26.1)
Higher education (18+) 12 (26.1) 10 (23.3)
Relevant professional training 7 (15.2) 6 (13.0)
Employment Working or studying 10 (21.3) 10 (21.3)
Not working 37 (78.7) 37 (78.7)
Mean (SD) Mean (SD)
Years using mental health services 13 (11.0) 14 (11.0)
Warwick-Edinburgh Mental Well-being Scale (WEMWBS) 3.19 (.76) 3.00 (.89)
Manchester Short Assessment of Quality of Life (MANSA) 4.05 (.85) 4.14 (1.01)
Positive Psychotherapy Inventory (PPI) 3.58 (.73) 3.44 (.80)
Brief Psychiatric Rating Scale (BPRS) 30.70 (8.81) 33.57 (8.42)
Short Depression-Happiness Scale (SDHS) 2.29 (.69) 2.48 (.76)
Integrative Hope Scale (IHS) 4.02 (.79) 3.72 (.85)
Rosenberg Self-Esteem Scale (RSES) 2.24 (.64) 2.09 (.66)
Savoring Beliefs Inventory (SBI) 4.80 (1.22) 4.48 (1.02)
Rogers Empowerment Scale (RES) 2.74 (.32) 2.71 (.32)
Sense of Coherence Scale (SCS) 4.18 (1.05) 3.81 (1.11)
Health of the Nation Outcome Scale (HoNoS) 7.29 (5.05) 9.62 (5.19)
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Table 2: Changes from baseline to follow-up (n=84, except for IHS n=83)
measure Group Mean difference (CI) p
WEMWBS
CONTROL 0.15 (-0.10-0.41) n.s.
INTERVENTION 0.26 (0.06-0.45) 0.010
MANSA
CONTROL 0.11 (-0.07-0.30) n.s.
INTERVENTION 0.34 (0.11-0.57) 0.004
PPI
CONTROL -0.02 (-0.15-0.11) n.s.
INTERVENTION 0.20 (0.06-0.35) 0.000
BPRS
CONTROL 0.78 (-1.16-2.72) n.s.
INTERVENTION -2.51 (-4.70--0.32) 0.026
SDHS
CONTROL -0.07 (-0.22-0.09) n.s.
INTERVENTION -0.24 (-0.45--0.03) 0.028
IHS
CONTROL 0.19 (-0.02-0.41) 0.080
INTERVENTION 0.21 (0.00-0.42) 0.048
RSES
CONTROL 0.05 (-0.07-0.18) n.s.
INTERVENTION 0.19 (0.04-0.34) 0.016
SBI
CONTROL 0.05 (-0.16-0.27) n.s.
INTERVENTION 0.08 (-0.15-0.32) n.s.
RES
CONTROL 0.01 (-0.07-0.08) n.s.
INTERVENTION 0.07 (-0.01-0.16) 0.079
SCS
CONTROL 0.17 (-0.03-0.36) 0.088
INTERVENTION 0.24 (0.01-0.46) 0.040
HONOS
CONTROL -0.37 (-1.91-1.18) n.s.
INTERVENTION 0.03 (-1.38-1.44) n.s.
WEMWBS: Warwick-Edinburgh Mental Well-Being Scale, MANSA: Manchester Short Assessment, PPI:
Positive Psychotherapy Inventory, BPRS: Brief Psychiatric Rating Scale, SDHS: Short Depression-
Happiness Scale, IHS: Integrative Hope Scale, RSES: Rosenberg Self-Esteem Scale, SBI: Savoring Beliefs
Inventory, RES: Rogers Empowerment Scale, SCS: Sense of Coherence Scale, HONOS: Health of the
Nation Outcome Scale
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Table 2: Intention to treat analysis (n=84, except for IHS n=83)
Follow-up mean (s.e.) Effect
sizeScale Control Intervention ANCOVA
n 41 43
WEMWBS 3.24 (0.10) 3.36 (0.10) F(1,81) = 0 .8, p = .37 .15
MANSA 4.21 (0.10) 4.42 (0.10) F(1,81) = 2.3, p = .13 .21
PPI 3.48 (0.07) 3.72 (0.07) F(1,81) = 5.9, p = .02 .30
BPRS 33.23 (.98) 29.37 (0.96) F(1,81) = 7.8, p = .006 .42
SDHS overall 2.34 (0.09) 2.13 (0.08) F(1,81) = 3.0, p = .09 .29
SDHS happiness 2.91 (.10) 3.03 (.10) F(1,81) = 0.6, p =. 42 .16
SDHS depression 2.60 (.10) 2.29 (.10) F(1,81) = 4.7, p = .03 .38
IHS 4.04 (0.10) 4.11 (0.10) F(1,81) = 0.3, p = .62 .08
RSES 2.21 (0.07) 2.37 (0.07) F(1,81) = 2.9, p = .09 .23
SBI 4.65 (0.11) 4.75 (0.10) F(1,81) = 0.4, p = .53 .09
RES 2.73 (0.04) 2.80 (0.04) F(1,81) = 2.0, p = .16 .22
SCS 4.12 (0.10) 4.26 (0.10) F(1,81) = 1.0, p = .32 .13
HONOS 8.53 (0.68) 8.14 (0.66) F(1,81) = 0.2, p = .68 .07
WEMWBS: Warwick-Edinburgh Mental Well-Being Scale, MANSA: Manchester Short
Assessment, PPI: Positive Psychotherapy Inventory, BPRS: Brief Psychiatric Rating Scale,
SDHS: Short Depression-Happiness Scale, IHS: Integrative Hope Scale, RSES: Rosenberg
Self-Esteem Scale, SBI: Savoring Beliefs Inventory, RES: Rogers Empowerment Scale,
SCS: Sense of Coherence Scale, HONOS: Health of the Nation Outcome Scale
Bold = significant differences
